Glaukos Corporation
NYSE:GKOS · New York Stock Exchange
-$0.18 today
Vol 0.46M · Avg 0.94M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:GKOS · Revenue to Net Income
Key Ratios
Analysis
$551.3M of revenue converted into -$189.3M of net income for the selected period. Gross margin is 78.1% and net margin is -33.6%, showing how much revenue survives after costs and taxes. EPS is $-3.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $507.4M +32.3% | $383.5M +21.9% | $314.7M +11.3% | $282.9M -3.8% | $294.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $114.2M +21.5% | $94.0M +24.4% | $75.6M +9.6% | $69.0M +3.5% | $66.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $393.2M +35.8% | $289.5M +21.0% | $239.1M +11.8% | $213.9M -5.9% | $227.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.5% +2.0pp | 75.5% -0.5pp | 76.0% +0.4pp | 75.6% -1.7pp | 77.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $150.6M +10.4% | $136.4M -1.7% | $138.8M +12.6% | $123.3M +22.1% | $101.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $329.3M +25.3% | $262.8M +17.3% | $224.1M +16.1% | $192.9M +7.6% | $179.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $479.9M +16.5% | $411.8M +12.0% | $367.8M +24.2% | $296.2M +13.8% | $260.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $42.3M +6.1% | $39.9M +5.1% | $38.0M +5.7% | $35.9M +4.4% | $34.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$146.1M -52.7% | -$95.6M -16.5% | -$82.1M -68.4% | -$48.8M -3208.2% | -$1.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -28.8% -3.8pp | -24.9% +1.2pp | -26.1% -8.9pp | -17.2% -16.7pp | -0.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$86.7M +29.1% | -$122.4M +4.9% | -$128.7M -56.4% | -$82.3M -150.4% | -$32.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -17.1% +14.8pp | -31.9% +9.0pp | -40.9% -11.8pp | -29.1% -17.9pp | -11.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $10.7M -3.5% | $11.1M +21.2% | $9.2M +285.9% | $2.4M +84.4% | $1.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.6M -53.8% | $10.0M -26.4% | $13.6M -0.6% | $13.7M +2.6% | $13.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$106.3M -357.5% | -$23.2M -362.2% | -$5.0M +68.8% | -$16.1M +1.7% | -$16.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$193.0M -32.6% | -$145.6M -8.9% | -$133.7M -35.9% | -$98.4M -99.8% | -$49.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -38.0% -0.1pp | -38.0% +4.5pp | -42.5% -7.7pp | -34.8% -18.0pp | -16.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$5.4M -794.0% | $771.0K -17.5% | $934.0K +21.9% | $766.0K +135.0% | $326.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$187.7M -28.2% | -$146.4M -8.7% | -$134.7M -35.8% | -$99.2M -100.0% | -$49.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -37.0% +1.2pp | -38.2% +4.6pp | -42.8% -7.7pp | -35.1% -18.2pp | -16.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -18.4% | -$3 +0.4% | -$3 -33.0% | -$2 -95.3% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -18.4% | -$3 +0.4% | -$3 -33.0% | -$2 -95.3% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.2M +8.4% | $52.8M +8.9% | $48.4M +2.1% | $47.4M +2.2% | $46.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.2M +8.4% | $52.8M +8.9% | $48.4M +2.1% | $47.4M +2.2% | $46.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$11.77B
Bruker Corporation
NASDAQ:BRKR
$8.44B
Alkermes plc
NASDAQ:ALKS
$7.55B
Oscar Health, Inc.
NYSE:OSCR
$7.35B
Arcellx, Inc.
ACLX
$6.73B
Teleflex Incorporated
NYSE:TFX
$5.50B
Bausch + Lomb Corporation
NYSE:BLCO
$5.31B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.87B
iRhythm Technologies, Inc.
NASDAQ:IRTC
$3.32B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.61B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GKOS generate?
Glaukos Corporation (GKOS) reported $507.44M of revenue in fiscal 2025.
Is GKOS profitable?
Glaukos Corporation (GKOS) reported -$187,691,000.00 of net income, with a net margin of -37.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.